Similar articles

• Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population.

  West R, Pesce A, West C, Crews B, Mikel C, Almazan P, Rosenthal M, Latyshev S. West R, et al. Pain Physician. 2010 Jan-Feb;13(1):71-8. Pain Physician. 2010. PMID: 20119465
• Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).

  Manchikanti L, Malla Y, Wargo BW, Cash KA, Pampati V, Damron KS, McManus CD, Brandon DE. Manchikanti L, et al. Pain Physician. 2010 Jan-Feb;13(1):E1-E22. Pain Physician. 2010. PMID: 20119473 Clinical Trial.
• A comparison of ONTRAK TESTCUP, abuscreen ONTRAK, abuscreen ONLINE, and GC/MS urinalysis test results.

  Crouch DJ, Cheever ML, Andrenyak DM, Kuntz DJ, Loughmiller DL. Crouch DJ, et al. J Forensic Sci. 1998 Jan;43(1):35-40. J Forensic Sci. 1998. PMID: 9456522
• Mechanism of interferences for gas chromatography/mass spectrometry analysis of urine for drugs of abuse.

  Wu AH. Wu AH. Ann Clin Lab Sci. 1995 Jul-Aug;25(4):319-29. Ann Clin Lab Sci. 1995. PMID: 7668815 Review.
• Clinical Benefits of Direct-to-Definitive Testing for Monitoring Compliance in Pain Management.

  Gencheva R, Petrides A, Kantartjis M, Tanasijevic M, Dahlin JL, Melanson S. Gencheva R, et al. Pain Physician. 2018 Nov;21(6):E583-E592. Pain Physician. 2018. PMID: 30508989 Review.